Organoid-based precision medicine in pancreatic cancer

Area of Science:

• Oncology
• Translational Medicine
• Cancer Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality with limited treatment options.
• Current PDAC therapies rely heavily on conventional chemotherapy, necessitating personalized approaches.
• Tumor heterogeneity in PDAC complicates treatment strategies and patient prognosis.

Purpose of the Study:

• To review precision oncology strategies for PDAC.
• To evaluate the role and limitations of organoid cultures in personalized PDAC medicine.
• To summarize evidence linking organoid predictions to patient treatment outcomes.

Main Methods:

• Review of current precision oncology in PDAC.
• Analysis of organoid culture applications in personalized medicine.
• Examination of preclinical studies correlating organoid drug response with clinical outcomes.
• Overview of organoid-based clinical trials in PDAC.

Main Results:

• Organoids recapitulate PDAC morphology and genetics, preserving patient-specific heterogeneity.
• Organoid cultures show potential for predicting individual patient response to therapies.
• Preclinical data suggest a correlation between in vitro organoid drug screening and in vivo patient response.

Conclusions:

• Organoid technology is a valuable tool for advancing personalized medicine in PDAC.
• Organoid-based drug screening can guide therapeutic decisions for improved treatment response.
• Further clinical validation of organoid models is crucial for widespread adoption in PDAC treatment.